Skip to main content

Table 1 Clinicopathologic characteristics according to Hans classification in diffuse large B cell lymphoma patients

From: Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma

Clinicopathologic characteristics

Total

GCB

Non-GCB

p-value

Age

 ≤ 60

53 (50%)

17 (63%)

31 (43%)

0.078#

 > 60

54 (50%)

10 (37%)

41 (57%)

 

Sex

 Male

61 (57%)

7 (26%)

34 (47%)

0.055#

 Female

46 (43%)

20 (74%)

38 (53%)

 

Primary site

 Nodal

54 (50%)

23 (85%)

51 (71%)

0.196†

 Extranodal

53 (49%)

4 (15%)

21 (29%)

 

B symptoms

 Absent

85 (79%)

25 (93%)

55 (76%)

0.088†

 Present

22 (21%)

2 (7%)

17 (24%)

 

ECOG PS

 < 2

97 (91%)

26 (96%)

64 (89%)

0.437†

 ≥ 2

10 (9%)

1 (4%)

8 (11%)

 

Serum lactate dehydrogenase

 Normal

54 (50%)

18 (69%)

32 (46%)

0.040#

 Elevated

50 (47%)

8 (31%)

38 (54%)

 

 Unknown

3 (3%)

   

No. of extranodal sites

 < 2

81 (76%)

17 (63%)

33 (46%)

0.129#

 ≥ 2

26 (24%)

10 (37%)

39 (54%)

 

Ann Arbor stage

 I–II

56 (52%)

17 (63%)

35 (49%)

0.203†

 III–IV

51 (48%)

10 (37%)

37 (51%)

 

International prognostic index

 0–2

71 (66%)

22 (81%)

44 (61%)

0.056#

 3–5

36 (34%)

5 (19%)

28 (39%)

 

Bone marrow involvement

 Absent

84 (79%)

25 (96%)

55 (85%)

0.168†

 Present

14 (13%)

1 (4%)

10 (15%)

 

 Unknown

9 (8%)

   

Bulky mass (cm)

 < 10

98 (92%)

25 (93%)

66 (92%)

> 0.999†

 ≥10

9 (8%)

2 (7%)

6 (8%)

 

Hans classification

 GCB

27 (25%)

27 (100%)

0 (0%)

NA

 Non-GCB

72 (67%)

0 (0%)

72 (100%)

 

 Unclassifiable

8 (8%)

   

BCL2 expression

 Negative

42 (39%)

13 (50%)

24 (33%)

0.133#

 Positive

65 (61%)

13 (50%)

48 (67%)

 

BCL6 expression

 Negative

60 (56%)

8 (30%)

44 (61%)

0.005#

 Positive

47 (44%)

19 (70%)

28 (39%)

 

CD10 expression

 Negative

92 (86%)

12 (44%)

72 (100%)

< 0.001†

 Positive

15 (14%)

15 (56%)

0 (0%)

 

MUM1 expression

 Negative

41 (38%)

25 (93%)

8 (11%)

< 0.001†

 Positive

66 (62%)

2 (7%)

64 (89%)

 

Treatment regimen

 R-CHOP

93 (87%)

23 (85%)

64 (89%)

0.731†

 Others

14 (13%)

4 (15%)

8 (11%)

 

Total N (%)

107 (100%)

   
  1. NA: not applicable; ECOG PS: the Eastern Cooperative Group Performance Status; GCB: germinal center B-cell like; R-CHOP: rituximab with cyclophosphamide–doxorubicin–vincristine–prednisone, GI: gastrointestinal
  2. p values were calculated by using Fisher’s exact test (2-sided)† or Pearson’s Chi square test (2-sided)#